A new study using “secret shoppers” found patients who are uninsured or covered by Medicaid often have a difficult time getting an appointment with a doctor who prescribes the opioid addiction medication buprenorphine.
A study of outpatient treatment for opioid addiction finds white patients are almost 35 times more likely than black patients to have a visit related to the addiction treatment medication buprenorphine, Kaiser Health News reports.
The National Institutes of Health will fund a study aimed at reducing opioid overdose deaths by 40 percent in three years, The Washington Post reports. The study will be conducted in four states hard hit by the opioid crisis.
Certain insurance plans are legally required to cover benefits for addiction treatment under the Affordable Care Act (ACA). A new report by Center on Addiction shows that ACA Plans sold in many states in 2017 did not comply with these requirements.
The U.S. Food and Drug Administration (FDA) has issued a new round of warnings and advisory letters to makers of dietary supplements, telling them not to falsely claim their products cure, prevent or treat serious diseases. Last year the FDA and the Federal Trade Commission sent warning letters to makers and distributors of 12 products sold as treatments for opioid addiction and withdrawal.
A new study finds many pharmacies in California don’t offer the opioid overdose antidote naloxone without a prescription, even though state law has allowed pharmacists to furnish naloxone without a physician’s prescription since 2016.
Making the opioid addiction medication buprenorphine more widely available outweighs the risk the drug will be diverted, addiction experts tell NPR. President Trump is expected to sign a bill that would increase access to the medication.